Publication: Cost–Utility Analysis of Dapagliflozin as an Add-On to Standard Treatment for Patients with Type 2 Diabetes and High Risk of Cardiovascular Disease in Thailand
14
Issued Date
2021-07-01
Resource Type
ISSN
18696961
18696953
18696953
Other identifier(s)
2-s2.0-85107520008
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
Diabetes Therapy. Vol.12, No.7 (2021), 1947-1963
Suggested Citation
Chaicharn Deerochanawong, Kriengsak Vareesangthip, Dilok Piyayotai, Dittaya Thongsuk, Nuch Pojchaijongdee, Unchalee Permsuwan Cost–Utility Analysis of Dapagliflozin as an Add-On to Standard Treatment for Patients with Type 2 Diabetes and High Risk of Cardiovascular Disease in Thailand. Diabetes Therapy. Vol.12, No.7 (2021), 1947-1963. doi:10.1007/s13300-021-01088-w Retrieved from: https://repository.li.mahidol.ac.th/handle/123456789/78094
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
Cost–Utility Analysis of Dapagliflozin as an Add-On to Standard Treatment for Patients with Type 2 Diabetes and High Risk of Cardiovascular Disease in Thailand
Abstract
Introduction: Diabetes treatment has incurred financial burden. We examined the cost–utility of adding dapagliflozin to the standard treatment for treating type 2 diabetes (T2DM) with cardiovascular risk in a Thai context. Methods: A two-part model, decision tree and Markov models, was developed to capture the benefits in terms of heart failure (HF) and chronic kidney disease. The model was used to estimate the lifetime costs and outcomes from a societal perspective. Costs were based on local data while the transitional probabilities and utilities were derived from the DECLARE-TIMI 58 clinical trial and published studies. Future costs and outcomes were discounted at an annual rate of 3%. The results were reported as incremental cost-effectiveness ratios (ICER). One-way and probabilistic sensitivity analyses were performed to investigate parameter uncertainty. Results: The increased cost of adding dapagliflozin from 8707 USD to 14,455 USD was associated with an increase in quality-adjusted life years (QALYs) from 9.28 to 9.58, yielding an ICER of 18,988 USD/QALY. Compared with the standard treatment, the dapagliflozin group acquired more clinical benefits in terms of fewer HF hospitalizations and macroalbuminuria. Sensitivity analyses revealed that with high prevalence of diabetic nephropathy of 29.4–43.9%, the ICER would decline to 5591–8014 USD/QALY. Conclusion: On the basis of the DECLARE study with low incidence of T2DM complications and 4.2 years of median follow-up duration, the add-on dapagliflozin results in an ICER of 18,988 USD/QALY, which exceeds the local threshold of 5310 USD/QALY. Dapagliflozin would show better value for money in the context of high prevalence of T2DM complications.